Omvoh and Entyvio are two non-anti-TNF biologics for moderate-to-severe Crohn's disease, each offering meaningful safety advantages over anti-TNFs through very different mechanisms. Omvoh is an IL-23 p19-selective biologic approved for Crohn's in January 2025 based on VIVID-1. Entyvio is gut-selective and has been a Crohn's treatment option since 2014. Patients comparing these drugs often prioritize long-term safety or are weighing alternatives after anti-TNF failure. This guide walks through the omvoh vs entyvio crohn's decision.
IL-23 vs Gut-Selective Mechanism
Omvoh (mirikizumab) binds the p19 subunit of interleukin-23, selectively blocking the Th17-driving cytokine central to Crohn's inflammation. Its immune effects are systemic but narrowly focused on IL-23. Entyvio (vedolizumab) binds the alpha-4-beta-7 integrin, a receptor found almost exclusively on gut-homing lymphocytes. By blocking these cells from entering inflamed intestinal tissue, Entyvio produces very little systemic immunosuppression. The mirikizumab vs vedolizumab distinction shapes how each drug performs in different patient populations and how their safety profiles look over the long term.
Efficacy in Crohn's
Omvoh's Crohn's efficacy rests on VIVID-1, which showed clinical response and endoscopic improvement in biologic-naive and biologic-experienced patients, with durable outcomes through two years of extension data. Entyvio's Crohn's data comes from GEMINI 2 and GEMINI 3, showing modest early response compared with placebo and improved outcomes with ongoing maintenance therapy. No head-to-head trial has directly compared Omvoh with Entyvio in Crohn's. Indirect comparisons suggest Omvoh may produce higher clinical remission rates and stronger endoscopic outcomes, while Entyvio delivers durable remission in patients who achieve response and offers the cleanest systemic safety profile of any IBD biologic.
Onset of Action
Omvoh produces clinically meaningful response by week 12 in most Crohn's patients, based on VIVID-1 data. Entyvio's onset is notably slower, with the label instructing clinicians to wait until week 14 before deciding whether the drug is working, and some patients continue to improve through week 26. For Crohn's patients with active symptoms who cannot tolerate a long ramp-up, Omvoh's faster onset is an advantage. For patients in less acute states or those prioritizing the narrowest systemic immune footprint, Entyvio's slower onset is generally manageable with supportive care.
Safety and Infection Risk
Both drugs have favorable safety profiles relative to anti-TNFs, but the risk signals differ. Entyvio's gut-selective action produces very low rates of systemic infection, and its long-term safety data is among the cleanest of any IBD biologic for non-GI infections. A 2024 Swedish registry study flagged a higher rate of serious gastrointestinal infections on vedolizumab compared with anti-TNFs, while overall systemic infection risk was lower. Omvoh's safety profile from VIVID-1 and the broader LUCENT UC experience has been consistent with the IL-23 class, showing low rates of serious infections and no unexpected safety signals. For omvoh vs entyvio side effects, injection-site and infusion-related reactions are mild for both drugs. Both carry boxed warnings related to serious infections.
Administration and Dosing
Omvoh for Crohn's uses IV induction at weeks 0, 4, and 8 (900 mg per infusion), followed by SC maintenance of 300 mg every 4 weeks. Entyvio starts with three 300 mg IV infusions at weeks 0, 2, and 6, followed by maintenance every 8 weeks. After IV induction, Entyvio patients who respond by week 6 can switch to a 108 mg subcutaneous pen every 2 weeks, per Takeda's dosing information. For Crohn's patients comparing long-term dosing frequency, Entyvio's every-8-week IV maintenance requires fewer doses than Omvoh's monthly SC maintenance, though Entyvio's SC conversion shifts patients to every-2-week injections. Patients who prefer to transition entirely to home-based maintenance may find Omvoh's all-SC maintenance phase convenient.
Anti-TNF Experienced Patients
For Crohn's patients who have failed an anti-TNF, both drugs have demonstrated efficacy in this population. VIVID-1 included biologic-experienced patients and showed meaningful response rates on Omvoh. Entyvio has anti-TNF experienced data as well, though response rates in this setting are lower than in biologic-naive cohorts. Real-world cohorts suggest that switching from an anti-TNF to either Omvoh or Entyvio delivers better outcomes than cycling within the anti-TNF class, with the mechanism change being the key driver. For patients who have cycled through one anti-TNF and are choosing between Omvoh and Entyvio, trial data tends to favor Omvoh on efficacy, while Entyvio offers the narrowest systemic safety profile.
Choosing With Your GI
For a Crohn's patient deciding between Omvoh and Entyvio, both drugs offer meaningful advantages over anti-TNFs. Omvoh tends to win on speed of onset and clinical remission rates with strong two-year durability data. Entyvio tends to win on the narrowest systemic safety footprint and less-frequent IV maintenance dosing. Your GI will weigh disease severity, prior biologic exposure, comorbidities, and insurance coverage. Before starting either drug, ask how response will be measured after induction (week 12 for Omvoh, week 14 for Entyvio), what to do if symptoms persist, and whether therapeutic drug monitoring will be part of your plan. A log of stool frequency, urgency, abdominal pain, and any new symptoms between visits helps your care team recognize early loss of response before a full flare develops.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.